SOX2 is identified as a downstream target of METTL3, and METTL3 is reported to maintain the expression of SOX2 by facilitating its methylation, thereby leading to the progression of glioma (Visvanathan et al., 2018) and colorectal cancer (Li et al., 2019). Here, METTL3 is linked to glioma.